Patients with progressive disease after one first-line platinum-based chemotherapy are randomised @:@ to oral afatinib ( starting dose @ mg once daily ) or IV methotrexate ( starting dose @ mg/m ( @ ) once weekly ) administered as monotherapy with best supportive care until progression or intolerable adverse events .